Zencore Biologics has a professional management team with vast experience in drug discovery, development, manufacturing, quality assurance and control, analytical science, and regulatory affairs in China and abroad. The total number of employees now exceeds 730+. Members of Zencore's leadership team have been building successful ventures in China for many years after returning to China from working in multinational companies overseas. They have scored many "Number Ones" in China and built a competent mid-level technical team with average over 10 years of experience in biopharmaceutical industries.
27 years' experience in biopharmaceutical industry, focus on fermentation, cell culture processing, and bioreactor design
Head of national key projects and World Bank loan projects (Chinese Academy of Sciences)
Developed a high-titer fed-batch cell culture platform with antibody titers up to 15 g/L (President's Award in AstraZeneca)
Developed a biosimilar cell culture platform for the first biosimilar marketed in China (Henlius)
Developed a high-yield cell culture platform which resulted in the first innovative anti- PD-1 antibody marketed in China (TopAlliance)
Founder and co-founder of several biotech and biopharmaceutical companies
Founded Zencore Biologics in 2017
MIT, Harvard University and University of Pittsburgh, etc.
AstraZeneca, Henlius, TopAlliance, etc.
Chinese Academy of Sciences (M.S.), Northeastern University (M.S.)
Tsinghua University (B.S.)
20+ years' experience in R&D andteam management in the field of biotechnology and biomedical industry
Scientist and head of technology management in Medarex, Amersham Pharmacia Biotech, Hologic and ABI/Life Technologies in the United States
Led the development of a variety of marketed biopharmaceutical products
Member of the Overseas High-level Talent Introduction Plan of Shanghai
Medarex, Amersham Pharmacia Biotech, Hologic, ABI / Life Technologies
New York University (Ph.D)
20+ years of R&D experience in innovative drugs (small molecule, antibody and fusion protein)
Participated in the establishment of Hansoh Pharma American R&D Center
Established a biotherapeutic team for R&D of antibody and ADC (Hansoh Bio)
Evaluated and initiated several antibody and ADC projects
Key contributor to AZD3427, which is currently in Phase I clinical trial (NCT04630067)
8 patents
Pfizer, MedImmune/AstraZeneca, Hansoh Bio, etc.
the State University of New York at Stony Brook (Ph.D.)
the University of California, San Diego (MBA)
20+ years' experience in recombinant protein/mAb based therapeutics, CAR-T, neurodegenerative disease therapeutics and diagnostics, and most recently in mRNA vaccines
Dozens of IND, BLA/NDA filings in China and United States
Adjunct professor of Jilin University
Editor of Mass Spectrometry
30 papers and 7 patents
Biogen, MedImmune/AstraZeneca, Teruisi, Bio-Gene, Gensciences, Abogen
University of Kent at Canterbury (Ph.D)
25 years of industrial experience in quality organizations
Successively served as QC supervisor, QC leader, QA leader, quality leader and quality authorized person
Extensive working experience in biologics projects from pre-clinical development to commercial phase
Pfizer, GSK, MSD, Roche, BI, Clover, Health Sciences Authority (Singapore)
Liaoning Normal University (M.S., B.S.)
20+ years of experience in biomedical analytical science, specializes in analytical development and quality control of antibodies, ADCs, and CAR-T drugs
Committed to the development and validation of drug analysis methods, successively serving as a researcher, deputy director, chief scientist, vice president, etc. in large companies such as Wyeth / Pfizer / GenScript / Cogengen Biologics, etc.
Wyeth, Pfizer, GenScript, Cogengen Biologics
Louisiana State University (Ph.D)
Loading...
